( CAMBRIDGE Mass.--(BUSINESS WIRE)--May ...)ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that clinical findings for three different TAP compounds for the treatment of solid tumors are to be reported at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to take place June 1-5, 2007 in Chicago, IL.

Trastuzumab-DM1 (abstract #1042)

"A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)."

-- Saturday, June 2, 2:00-6:00 pm: Breast Cancer - Metastatic General Poster Session (poster #G4).

-- Trastuzumab-DM1 is in development by Genentech.

HuC242-DM4 (abstract #3062)

"A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors."

-- Sunday, June 3, 8:00 am-12:00 noon: Developmental Therapeutics: Immunotherapy General Poster Session (poster #F14).

-- HuC242-DM4 is wholly owned by ImmunoGen.

HuN901-DM1 (abstract #18084)

"Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma."

-- To be published as abstract in the Journal of Clinical Oncology.

-- HuN901-DM1 is wholly owned by ImmunoGen.

About ImmunoGen's TAP Technology

ImmunoGen created its TAP technology to enhance the anticancer activity of tumor-targeting antibodies while maintaining a favorable tolerability profile. The Company attaches to an antibody one of ImmunoGen's proprietary cell-killing agents. The antibody serves to deliver the agent specifically to cancer cells and the agent serves to kill the cancer cells. The agent is attached using one of the Company's "linkers." ImmunoGen has developed alte
'"/>

Page: 1 2 3
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product